{"organizations": [], "uuid": "0d104265518963176ca84bf96c39c28f8a08d54b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-durect-corp-says-commenced-patient/brief-durect-corp-says-commenced-patient-dosing-in-a-phase-2a-clinical-trial-of-dur-928-idUSFWN1QG0SB", "country": "US", "domain_rank": 408, "title": "BRIEF-Durect Corp Says Commenced Patient Dosing In A Phase 2A Clinical Trial Of Dur-928", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-26T13:46:00.000+02:00", "replies_count": 0, "uuid": "0d104265518963176ca84bf96c39c28f8a08d54b"}, "author": "", "url": "https://www.reuters.com/article/brief-durect-corp-says-commenced-patient/brief-durect-corp-says-commenced-patient-dosing-in-a-phase-2a-clinical-trial-of-dur-928-idUSFWN1QG0SB", "ord_in_thread": 0, "title": "BRIEF-Durect Corp Says Commenced Patient Dosing In A Phase 2A Clinical Trial Of Dur-928", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-durect corp", "sentiment": "negative"}, {"name": "2a clinical trial of dur-928 reuters", "sentiment": "none"}, {"name": "sec", "sentiment": "none"}, {"name": "psc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "durect corp", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 26, 2018 / 11:47 AM / in 8 minutes BRIEF-Durect Corp Says Commenced Patient Dosing In A Phase 2A Clinical Trial Of Dur-928 Reuters Staff 1 Min Read Feb 26 (Reuters) - Durect Corp: * DURECT CORP SAYS COMMENCED PATIENT DOSING IN A PHASE 2A CLINICAL TRIAL OF DUR-928 IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) - SEC FILING * DURECT CORP - EXPECTS TO GENERATE DATA FROM PHASE 2A CLINICAL TRIAL DURING COURSE OF 2018 Source text: [ bit.ly/2EU3GRm ] Further company coverage:", "external_links": [], "published": "2018-02-26T13:46:00.000+02:00", "crawled": "2018-02-26T14:05:42.005+02:00", "highlightTitle": ""}